Spanish Office REITs Stock News

Línea Directa Aseguradora Compañía de Seguros y Reaseguros went into today trading at €1.26 after a steady few months, with the stock up about 6% over 90 days. The market has been pricing in a mixed story, yet H1 2026 came through with a clear headline. Net profit reached €52.1m with a return on equity of 23.3%, and the Solvency II capital ratio stood at 196.3% even after an interim dividend. In the short term, that combination of profitability and capital strength is what drew attention. The...

Neinor Homes closed at €16.27 after a muted few months, with the stock roughly flat over 90 days. Today’s H1 2026 release puts the focus squarely on profit quality rather than price action. The headline is a solid profit print sitting on top of a balance sheet that still carries meaningful interest costs, with trailing net margin at 10.7% and management flagging that interest payments are not comfortably covered by earnings. Short term traders may shrug. Long term holders now have to weigh...

Why the latest earnings and guidance update matters for Laboratorios Farmaceuticos Rovi stock Laboratorios Farmaceuticos Rovi (BME:ROVI) has drawn fresh attention after reporting half year 2026 results with higher sales and net income, while keeping its full year operating revenue growth guidance unchanged. This combination of stronger interim earnings and steady expectations for low to mid single digit operating revenue growth in 2026 provides investors with new information on how the...

Why Vidrala’s latest earnings matter for shareholders Vidrala (BME:VID) has moved back into focus after its half year 2026 earnings on 23 July, with rising profit, firmer margins and a clear reaffirmation of full year financial targets. For the six months to 30 June 2026, Vidrala reported sales of €755.04 million compared with €751.14 million a year earlier. Net income was €117.4 million against €107.84 million, with basic earnings per share at €3.36 versus €3.0667. See our latest analysis...

Elecnor (BME:ENO) has just posted its H1 2026 results with the trailing twelve months showing revenue of €4.4b and basic EPS of €1.52, backed by net income of €128.6m. Over recent reporting periods, the company has seen revenue move from €2.0b and EPS of €0.59 in H1 2025 to €2.4b and EPS of €0.72 in H2 2025, while the prior H2 2024 period was marked by a net income loss of €143.1m on €2.1b of revenue. Overall, margins look steadier than a year ago, leaving investors to consider where...

The European stock market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 0.46% amid robust corporate earnings and geopolitical tensions impacting oil prices. As investors navigate these complex conditions, identifying stocks that may be trading below their intrinsic value can present opportunities for those seeking potential growth in a volatile environment.

How Enagás earnings set the context for the stock Enagás (BME:ENG) has just reported half year 2026 results, with sales of €444.63 million and net income of €126.91 million, both lower than the same period a year earlier. Basic and diluted earnings per share from continuing operations were €0.49, compared with €0.68 a year ago. This gives investors fresh information to reassess how the stock’s current price reflects these figures. See our latest analysis for Enagás. Since the H1 2026 earnings...

Banco de Sabadell (BME:SAB) has reported Q2 2026 results with total revenue of €1,396 million and net income of €624 million, setting the tone for how the rest of the year may shape up for shareholders. The company has seen quarterly revenue move from €1,362 million in Q4 2025 to €1,046 million in Q1 2026 and then to €1,396 million in Q2 2026, while basic EPS tracked at €0.0776 in Q4 2025 and €0.0705 in Q1 2026. This gives investors a clearer view of how the top and bottom lines are pacing...

Grifols recently reported that the first patients have been dosed in two Phase 3 trials to expand U.S. labels for its flagship immunoglobulin therapies, GAMUNEX-C and XEMBIFY, targeting secondary immunodeficiency in certain blood cancers and chronic inflammatory demyelinating polyradiculoneuropathy. This push to broaden indications for existing plasma-derived products highlights how Grifols is trying to deepen its presence in complex, chronic immune-related conditions where immunoglobulin...

Atresmedia Corporación de Medios de Comunicación (BME:A3M) has drawn attention after reporting half year 2026 earnings, with sales of €458.38 million alongside lower net income and earnings per share compared with the previous year. See our latest analysis for Atresmedia Corporación de Medios de Comunicación. Atresmedia Corporación de Medios de Comunicación’s latest half year earnings have landed alongside a share price of €5.08, with a 1 day share price return of 2.83% and a 7 day share...

Investors in Laboratorios Farmaceuticos Rovi, S.A. ( BME:ROVI ) had a good week, as its shares rose 8.6% to close at...

Investors in Indra Sistemas, S.A. ( BME:IDR ) had a good week, as its shares rose 8.9% to close at €53.36 following the...

Vidrala, S.A. ( BME:VID ) shareholders are probably feeling a little disappointed, since its shares fell 5.3% to €86.00...

Tubacex (BME:TUB) has released its Q2 2026 results with revenue of €170.6 million and a net loss of €0.6 million, setting a mixed headline for investors watching the stock around €3.12. The company has seen quarterly revenue move from €180.8 million in Q2 2025 to €170.6 million in Q2 2026, while net income shifted from a profit of €4.4 million to a small loss of €0.6 million over the same period, and EPS in Q2 2025 was €0.04 compared with €0.01 in Q1 2026. Overall, Tubacex is showing solid...

Almirall (BME:ALM) has put fresh numbers on the table for Q2 2026, reporting revenue of €313.2 million and net income of €24.3 million, alongside trailing twelve month EPS of €0.28 on revenue of €1.16 billion and net income of €59.1 million. The company has seen revenue move from €262.2 million in Q3 2025 to €288.9 million in Q4 2025, €292.4 million in Q1 2026 and now €313.2 million in Q2 2026, with quarterly net income shifting from €12.5 million to €7.1 million, €15.3 million and €24.3...

Why Bankinter's Latest Earnings Matter for Investors Bankinter (BME:BKT) has attracted fresh attention after reporting half year 2026 results, with net interest income of €1,173.67 million and net income of €605.26 million, both above the prior year period. See our latest analysis for Bankinter. Since those half year figures, Bankinter's share price has gained 10.97% over the past month and 15.77% over the last quarter, while the 1 year total shareholder return of 37.12% and very large 5 year...

Acerinox (BME:ACX) stock is in focus after the company reported half-year 2026 results, with sales of €2,969.47 million and net income of €76.6 million, compared with a net loss a year earlier. See our latest analysis for Acerinox. The earnings swing back to profit appears to have shifted sentiment, with Acerinox’s share price up 10.7% over the last day and delivering a 90 day share price return of 38.37%. The 1 year total shareholder return stands at 85.98%, suggesting momentum has been...

It's been a good week for Enagás, S.A. ( BME:ENG ) shareholders, because the company has just released its latest...

It's been a good week for Naturgy Energy Group, S.A. ( BME:NTGY ) shareholders, because the company has just released...

Banco de Sabadell (BME:SAB) drew investor attention after releasing its Q2 2026 results, reporting net income of €624 million for the quarter and €971 million for the first half of the year. See our latest analysis for Banco de Sabadell. Following the Q2 2026 earnings release, Banco de Sabadell’s share price has picked up short term momentum, with a 1 month share price return of 9.14%, while the year to date share price return remains down 2.26%. Over the longer term, total shareholder...

The new US tariff regime under Section 301 is quietly reshaping the playing field for global exporters, and European stocks are right in the middle of it. With lower duties for key countries like France, the UK, Germany, Spain, Belgium, and Italy, and higher rates for rivals such as Brazil, some European exporters now sit in a more favorable position in US trade. This article looks at how that shift connects to large European companies on our European Exporters screener and reveals 3 stocks...

CIE Automotive (BME:CIE) has drawn attention after reporting half year 2026 earnings, with sales, revenue, net income and earnings per share all higher than the figures reported a year earlier. See our latest analysis for CIE Automotive. Despite the stronger half year figures, CIE Automotive’s recent share price performance has been weak, with the stock at €25.8 and a year to date share price decline of 14.99%. However, the 5 year total shareholder return of 17.34% points to a more resilient...

Atresmedia Corporación de Medios de Comunicación (BME:A3M) has just reported its H1 2026 results, with revenue of €387.1 million and basic EPS of €0.244 on a trailing twelve month basis, set against trailing net income of €54.7 million. The company has seen revenue move from €395.7 million in H2 2024 to €506.6 million in H1 2025 and €387.1 million in H2 2025, while basic EPS shifted from €0.227 to €0.283 and then a small loss in H2 2025. This frames today’s update against a mixed recent...

Repsol’s share price has delivered very strong gains over the past five years, yet there is a clear split in what current valuation tools are signalling, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to sizeable upside while market based multiples suggest the stock is closer to expensive territory. The stock has returned 256.9% over five years, which raises the bar for any further upside to be supported by fundamentals. Recent profit strength and expansion in areas...